{"id":"xolair-symbicort","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Cough"},{"rate":"5-10%","effect":"Pharyngitis"},{"rate":"5-10%","effect":"Sinusitis"}]},"_chembl":{"chemblId":"CHEMBL1370","moleculeType":"Small molecule","molecularWeight":"430.54"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Omalizumab works by binding to IgE, preventing it from binding to its receptor on mast cells and basophils, which reduces the release of histamine and other mediators involved in allergic reactions. Budesonide is a corticosteroid that reduces inflammation in the airways, while formoterol is a long-acting beta2-adrenergic receptor agonist that relaxes bronchial muscles and improves airflow.","oneSentence":"Xolair (omalizumab) is an anti-IgE antibody that blocks the action of IgE, a protein involved in allergic reactions, while Symbicort (budesonide and formoterol) is a combination of a corticosteroid and a long-acting beta2-adrenergic receptor agonist that reduces inflammation and bronchospasm in the airways.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:55.041Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance and control"},{"name":"Chronic idiopathic urticaria"}]},"trialDetails":[{"nctId":"NCT04607629","phase":"PHASE3","title":"An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial Asthma","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2018-06-20","conditions":"Bronchial Asthma","enrollment":192}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["omalizumab & (budesonide+formoterol)"],"phase":"phase_3","status":"active","brandName":"Xolair® + Symbicort®","genericName":"Xolair® + Symbicort®","companyName":"AO GENERIUM","companyId":"ao-generium","modality":"Biologic","firstApprovalDate":"","aiSummary":"Xolair (omalizumab) is an anti-IgE antibody that blocks the action of IgE, a protein involved in allergic reactions, while Symbicort (budesonide and formoterol) is a combination of a corticosteroid and a long-acting beta2-adrenergic receptor agonist that reduces inflammation and bronchospasm in the airways. Used for Asthma maintenance and control, Chronic idiopathic urticaria.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}